• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

停止使用芬戈莫德后出现进行性多灶性白质脑病或免疫重建炎症综合征?一例报告。

Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report.

机构信息

Department of Neurology, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, Lithuania.

Department of Neurology, Lithuanian University of Health Sciences Clinical, Kaunas, Lithuania.

出版信息

BMC Neurol. 2022 Aug 19;22(1):306. doi: 10.1186/s12883-022-02839-3.

DOI:10.1186/s12883-022-02839-3
PMID:35986243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9392231/
Abstract

BACKGROUND

Fingolimod is associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML); however, its discontinuation may cause severe immune reconstitution inflammatory syndrome (IRIS). As both of these conditions (especially fingolimod induced PML) are rarely described in medical case reports distinguishing between PML-IRIS and MS-IRIS may be diagnostically challenging.

CASE PRESENTATION

We report a patient with severe clinical decline (Expanded Disability Status Scale (EDSS) increasing from 3.5 to 7.5) and multiple, large, contrast-enhancing lesions on brain magnetic resonance imaging (MRI) a few months after fingolimod withdrawal. The diagnostic possibilities included IRIS due to fingolimod withdrawal versus PML-IRIS. The JC virus (JCV) antibody index was positive (2.56); however, cerebrospinal fluid (CSF) JCV real-time polymerase chain reaction (JCV-PCR) was negative and brain biopsy was not performed. After a long course of aggressive treatment (several pulsed methylprednisolone infusions, plasmapheresis, intravenous dexamethasone, oral mirtazapine) the patient gradually recovered (EDSS 2.5) and MRI lesions decreased.

CONCLUSIONS

This case report demonstrates the importance of monitoring patients carefully after the discontinuation of fingolimod for PML-IRIS and rebound MS with IRIS as these conditions may manifest similarly.

摘要

背景

芬戈莫德会增加发生进行性多灶性白质脑病(PML)的风险;然而,停用芬戈莫德可能会导致严重的免疫重建炎症综合征(IRIS)。由于这两种情况(特别是由芬戈莫德引起的 PML)在医学病例报告中很少描述,因此区分 PML-IRIS 和 MS-IRIS 可能具有诊断挑战性。

病例介绍

我们报告了一例患者,在停用芬戈莫德几个月后出现严重的临床恶化(扩展残疾状态量表(EDSS)从 3.5 增加到 7.5)和大脑磁共振成像(MRI)上多个大的对比增强病变。诊断的可能性包括因停用芬戈莫德而导致的 IRIS 与 PML-IRIS。JC 病毒(JCV)抗体指数阳性(2.56);然而,脑脊液(CSF)JCV 实时聚合酶链反应(JCV-PCR)为阴性,未进行脑活检。经过长时间的积极治疗(多次脉冲甲基强的松龙输注、血浆置换、静脉注射地塞米松、口服米氮平),患者逐渐恢复(EDSS 2.5),MRI 病变减少。

结论

本病例报告表明,在停用芬戈莫德后,密切监测患者的 PML-IRIS 和反弹 MS 与 IRIS 非常重要,因为这些情况可能表现相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6c2/9392231/b103aef76d9a/12883_2022_2839_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6c2/9392231/7d3df781a04d/12883_2022_2839_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6c2/9392231/d63d1c258767/12883_2022_2839_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6c2/9392231/b103aef76d9a/12883_2022_2839_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6c2/9392231/7d3df781a04d/12883_2022_2839_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6c2/9392231/d63d1c258767/12883_2022_2839_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b6c2/9392231/b103aef76d9a/12883_2022_2839_Fig3_HTML.jpg

相似文献

1
Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report.停止使用芬戈莫德后出现进行性多灶性白质脑病或免疫重建炎症综合征?一例报告。
BMC Neurol. 2022 Aug 19;22(1):306. doi: 10.1186/s12883-022-02839-3.
2
Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.在一名复发缓解型多发性硬化症患者中,采用包括 pembrolizumab 在内的管理方法治疗那他珠单抗相关性进行性多灶性白质脑病。
Mult Scler. 2023 Feb;29(2):301-306. doi: 10.1177/13524585221137279. Epub 2022 Nov 30.
3
Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data.芬戈莫德相关性进行性多灶性白质脑病中广泛免疫重建炎症综合征:附 7T MRI 数据的一例病例报告。
BMC Neurol. 2019 Aug 9;19(1):190. doi: 10.1186/s12883-019-1407-2.
4
Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.接受那他珠单抗治疗的多发性硬化症患者的免疫重建炎症综合征:4例病例系列
Clin Ther. 2016 Mar;38(3):670-5. doi: 10.1016/j.clinthera.2016.01.010. Epub 2016 Feb 5.
5
Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.肺移植后免疫抑制剂剂量减少导致可能的进行性多灶性白质脑病-免疫重建炎症综合征:病例报告及文献复习。
BMC Neurol. 2019 Oct 31;19(1):263. doi: 10.1186/s12883-019-1493-1.
6
Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.在停用那他珠单抗后接受芬戈莫德治疗的多发性硬化症患者中,静脉注射免疫球蛋白治疗进行性多灶性白质脑病-免疫重建炎症综合征。
J Clin Neurosci. 2015 Mar;22(3):598-600. doi: 10.1016/j.jocn.2014.08.016. Epub 2014 Dec 15.
7
Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.多发性硬化症患者接受那他珠单抗治疗后脑脊液中 JC 病毒聚合酶链反应结果与进行性多灶性白质脑病病变体积的相关性。
JAMA Neurol. 2018 Jul 1;75(7):827-833. doi: 10.1001/jamaneurol.2018.0094.
8
Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.非典型多发性硬化病变或进行性多灶性白质脑病病变:这就是问题所在。
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620939802. doi: 10.1177/2324709620939802.
9
Severe Progressive Multifocal Leukoencephalopathy (PML) and Spontaneous Immune Reconstitution Inflammatory Syndrome (IRIS) in an Immunocompetent Patient.免疫健全患者的严重进行性多灶性白质脑病(PML)和自发性免疫重建炎症综合征(IRIS)。
Front Immunol. 2019 May 28;10:1188. doi: 10.3389/fimmu.2019.01188. eCollection 2019.
10
Immune reconstitution inflammatory syndrome in natalizumab-associated PML.与纳武单抗相关的进行性多灶性白质脑病中的免疫重建炎症综合征。
Neurology. 2011 Sep 13;77(11):1061-7. doi: 10.1212/WNL.0b013e31822e55e7. Epub 2011 Aug 10.

引用本文的文献

1
Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.使用帕博利珠单抗治疗进展性多灶性白质脑病:1例接受芬戈莫德治疗的多发性硬化症患者的病例
J Neurol. 2024 Feb;271(2):729-732. doi: 10.1007/s00415-023-12055-9. Epub 2023 Nov 1.
2
Fingolimod-associated progressive multifocal leukoencephalopathy in a multiple sclerosis patient with a good response to filgrastim.一名对非格司亭反应良好的多发性硬化症患者发生与芬戈莫德相关的进行性多灶性白质脑病。
J Neurol. 2023 Nov;270(11):5196-5200. doi: 10.1007/s00415-023-11865-1. Epub 2023 Jul 17.

本文引用的文献

1
Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.进行性多灶性白质脑病与 JC 病毒相关疾病谱。
Nat Rev Neurol. 2021 Jan;17(1):37-51. doi: 10.1038/s41582-020-00427-y. Epub 2020 Nov 20.
2
Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.非典型多发性硬化病变或进行性多灶性白质脑病病变:这就是问题所在。
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620939802. doi: 10.1177/2324709620939802.
3
Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations.
芬戈莫德反弹:临床经验与管理考量综述
Neurol Ther. 2019 Dec;8(2):241-250. doi: 10.1007/s40120-019-00160-9. Epub 2019 Nov 1.
4
Development of demyelinating lesions in progressive multifocal leukoencephalopathy (PML): Comparison of magnetic resonance images and neuropathology of post-mortem brain.进行性多灶性白质脑病(PML)脱髓鞘病变的发展:磁共振成像与尸检脑组织神经病理学的比较。
Neuropathology. 2019 Aug;39(4):294-306. doi: 10.1111/neup.12562. Epub 2019 Jun 2.
5
Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.芬戈莫德撤药后多发性硬化症复发的频率及临床特征
CNS Neurosci Ther. 2018 Oct;24(10):984-986. doi: 10.1111/cns.12992. Epub 2018 Jun 13.
6
Progressive multifocal leukoencephalopathy after fingolimod treatment.进行性多灶性白质脑病继发于芬戈莫德治疗后。
Neurology. 2018 May 15;90(20):e1815-e1821. doi: 10.1212/WNL.0000000000005529. Epub 2018 Apr 18.
7
Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.了解免疫调节治疗多发性硬化症患者进行性多灶性白质脑病的风险:鸟瞰图。
Front Immunol. 2018 Feb 2;9:138. doi: 10.3389/fimmu.2018.00138. eCollection 2018.
8
Neurological safety of fingolimod: An updated review.芬戈莫德的神经安全性:最新综述。
Clin Exp Neuroimmunol. 2017 Aug;8(3):233-243. doi: 10.1111/cen3.12397. Epub 2017 Jun 18.
9
Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.停用芬戈莫德后外周免疫库的重建
Mult Scler. 2017 Aug;23(9):1225-1232. doi: 10.1177/1352458517713147.
10
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.没有证据表明血浆置换疗法对那他珠单抗相关的进行性多灶性白质脑病有有益效果。
Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740. Epub 2017 Feb 22.